ImmunityBio (NASDAQ:IBRX) Shares Gap Up – Time to Buy?

ImmunityBio, Inc. (NASDAQ:IBRX) shares gapped up prior to trading on Tuesday . The stock had previously closed at $5.95, but opened at $6.26. ImmunityBio shares last traded at $6.0450, with a volume of 5,182,368 shares changing hands.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: EU conditional authorization for ANKTIVA+BCG (NMIBC CIS) substantially enlarges the addressable market and supports international revenue growth prospects. ImmunityBio (IBRX) Is Up 29.0% After EU Clears First ANKTIVA+BCG Immunotherapy For NMIBC CIS
• Positive Sentiment: New distribution partnership with Accord Healthcare and opening an Irish subsidiary create a clear commercial pathway for EU launch and supply/logistics scale‑up across member states. This reduces execution risk versus relying on ad hoc country rollouts. ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
• Positive Sentiment: Regulatory approvals now span ~33 countries (including recent Saudi activity) and FY25 commercial traction (reported strong revenue growth) underpin upside expectations as ANKTIVA scales internationally. ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up
• Neutral Sentiment: Technical momentum is strong — the stock shows a confirmed “golden cross” and is trading well above its 200‑day average, which may attract momentum and retail flows but is not a fundamental revenue guarantee. ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average
• Neutral Sentiment: Volume and price spikes have been pronounced; elevated trading can amplify moves in either direction and may reflect short‑term positioning rather than long‑term fundamental value. ImmunityBio stock soars after EU authorization for bladder cancer therapy
• Negative Sentiment: An investor litigation inquiry (Pomerantz law firm) introduces legal and disclosure risk that can create an overhang on the share price and lead to costs or settlements. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. – IBRX
• Negative Sentiment: Analysts and market commentary flag valuation and momentum concerns after the rally — high expectations mean future trial setbacks, slower uptake, or post‑marketing conditions tied to the EU authorization could trigger sharp downside. ImmunityBio’s EU Anktiva Nod Sparks Questions On Valuation And Momentum

Analyst Ratings Changes

IBRX has been the subject of a number of recent research reports. BTIG Research lifted their price target on shares of ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of ImmunityBio in a research report on Tuesday. Piper Sandler boosted their target price on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. HC Wainwright raised their price target on ImmunityBio from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.80.

ImmunityBio Stock Up 0.8%

The firm has a fifty day simple moving average of $4.22 and a 200-day simple moving average of $3.03. The company has a market cap of $8.48 billion, a PE ratio of -21.00 and a beta of 0.16.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 151,967 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the transaction, the director owned 3,091,604 shares of the company’s stock, valued at $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Christobel Selecky sold 50,000 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 226,967 shares of company stock worth $1,531,912. 69.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Mariner LLC raised its holdings in shares of ImmunityBio by 10.5% in the fourth quarter. Mariner LLC now owns 17,814 shares of the company’s stock valued at $35,000 after buying an additional 1,689 shares during the last quarter. Sanctuary Advisors LLC increased its position in ImmunityBio by 6.9% in the 4th quarter. Sanctuary Advisors LLC now owns 29,547 shares of the company’s stock valued at $59,000 after acquiring an additional 1,918 shares during the period. Sequoia Financial Advisors LLC increased its position in ImmunityBio by 8.6% in the 4th quarter. Sequoia Financial Advisors LLC now owns 28,783 shares of the company’s stock valued at $57,000 after acquiring an additional 2,271 shares during the period. Mutual Advisors LLC raised its stake in ImmunityBio by 9.0% during the 4th quarter. Mutual Advisors LLC now owns 30,200 shares of the company’s stock valued at $60,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in ImmunityBio by 4.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 75,776 shares of the company’s stock worth $150,000 after acquiring an additional 3,280 shares during the period. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.